Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motexafin Gadolinium in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
NCT00086034Phase 2Completed
- Sponsor
- Pharmacyclics
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of motexafin gadolinium in Indolent Non-Hodgkin Lymphoma (INHL), sponsored by Pharmacyclics. Status: completed.
02
Drugs
motexafin gadolinium
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT00086034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086034.